Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct 10;42(29):3383-3386.
doi: 10.1200/JCO.24.01147. Epub 2024 Sep 4.

New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years

Christine M Lovly  1
Affiliations
Editorial

New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years

Christine M Lovly. J Clin Oncol. .

Abstract

In the article that accompanies this editorial, Dr. Solomon and colleagues present a post-hoc analysis of investigator-assessed efficacy outcomes, safety, and biomarker analyses encompassing approximately 5 years’ worth of data from the CROWN trial (NCT03052608) of lorlatinib compared with crizotinib in patients with treatment naïve advanced / metastatic ALK+ NSCLC demonstrating a PFS benefit for lorlatinib which exceeds 5 years and a 96% probability of preventing brain metastases within this time frame. These updated data are unprecedented for the treatment of ALK+ NSCLC, and for NSCLC treated with targeted therapies in general, making a compelling argument for lorlatinib as the preferred first line ALK TKI.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
A New Benchmark for Targeted Therapies in Lung Cancer Treatment
See this image and copyright information in PMC

Comment on

References

    1. Soda M, Choi YL, Enomoto M, et al. : Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–6, 2007 - PubMed
    1. Mok T, Camidge DR, Gadgeel SM, et al. : Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 31:1056–1064, 2020 - PubMed
    1. Camidge DR, Kim HR, Ahn MJ, et al. : Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. J Thorac Oncol 16:2091–2108, 2021 - PubMed
    1. Horn L, Wang Z, Wu G, et al. : Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA Oncol 7:1617–1625, 2021 - PMC - PubMed
    1. Shaw AT, Bauer TM, de Marinis F, et al. : First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med 383:2018–2029, 2020 - PubMed

MeSH terms